IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. (Q37773168)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635099%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

review article

1 reference

title

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635099%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635099%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

3

Jacob George

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635099%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

David R Booth

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635099%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

16 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635099%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastroenterology

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635099%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635099%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635099%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

903-910

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635099%20AND%20SRC:MED&resulttype=core&format=json

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0287-4

IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0287-4

Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0287-4

IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0287-4

An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0287-4

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

12 December 2020

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

12 December 2020

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

12 December 2020

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

1 reference

12 December 2020

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

1 reference

12 December 2020

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

12 December 2020

NIH Consensus Statement on Management of Hepatitis C: 2002

1 reference

12 December 2020

Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines

1 reference

12 December 2020

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

1 reference

12 December 2020

Interferon type I gene expression in chronic hepatitis C.

1 reference

12 December 2020

Course and outcome of hepatitis C

1 reference

12 December 2020

Lambda interferon inhibits hepatitis B and C virus replication

1 reference

12 December 2020

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

1 reference

12 December 2020

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes

1 reference

12 December 2020

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

12 December 2020

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

12 December 2020

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

1 reference

12 December 2020

Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses

1 reference

12 December 2020

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

12 December 2020

Role of deficient type III interferon-λ production in asthma exacerbations

1 reference

12 December 2020

Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling

1 reference

12 December 2020

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

1 reference

12 December 2020

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

1 reference

12 December 2020

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

12 December 2020

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

1 reference

12 December 2020

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

1 reference

12 December 2020

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

1 reference

12 December 2020

1 reference

12 December 2020

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

1 reference

12 December 2020

10.1007/S00535-010-0287-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20635099%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference